Uncategorized

Summit, Merck must navigate new regulatory terrain in China-first cancer landscape

Summit, Merck must navigate new regulatory terrain in China-first cancer landscape

Published

on

Summit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be required for Summit and China-based partner Akeso—and other transnational tandems—to secure FDA approval?​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version